Marketing Department

G protein-coupled receptors (GPCRs) are one of the most important signal transduction protein families in human cell membranes, regulating a wide range of physiological processes from vision and olfaction to cardiovascular function. Among them, the Angiotensin II Type 1 Receptor (AT1R) plays a central role in blood pressure regulation, fluid balance, and cardiovascular diseases. However, the activation mechanism of peptide ligand-binding GPCRs like AT1R has long been a research bottleneck, as traditional methods struggled to capture their active conformations, hindering the precise development of targeted therapeutics. A research team from Harvard Medical School, Duke University, and other institutions has successfully overcome this challenge using synthetic nanobody technology. Their findings, published in Cell, pave a new path for GPCR research and drug development.

CD7 is a transmembrane glycoprotein primarily expressed on the surface of T cells, NK cells, and their precursor cells. It is highly expressed, especially in hematological tumors such as T-cell acute lymphoblastic leukemia (T-ALL) and lymphoma. As a member of the immunoglobulin superfamily, CD7 is involved in T cell activation, adhesion, and signal transduction, playing an important role in lymphocyte development and immune response. It is a significant marker for T-cell malignancies. Due to its specific expression and persistence in pathological states, CD7 has become an ideal target for developing novel immunotherapeutic strategies.